echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > SHPL-49 injection, a new class 1 chemical drug of Shanghai Hutchison Pharmaceuticals, obtained NMPA and FDA clinical trial approval

    SHPL-49 injection, a new class 1 chemical drug of Shanghai Hutchison Pharmaceuticals, obtained NMPA and FDA clinical trial approval

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Shanghai, October 20, 2021/PRNewswire/ - On October 11 and October 18, SHPL-49 injection developed by Shanghai Hehuang Pharmaceutical Co.


    Stroke is the second leading cause of death in the world, and it is also the disease with the highest rate of disability in a single disease.


    According to the pathological classification, stroke can be divided into ischemic stroke (cerebral ischemic stroke, CIS) and hemorrhagic stroke (cerebralhemorrhagic stroke).


    Effective treatment in the acute phase of ischemic stroke (within 2 weeks after the onset) is the key to affecting the prognosis and recovery of patients, but there is a lack of clinically effective drugs for the treatment of acute ischemic stroke


    For patients with acute ischemic stroke, the clinical goal is to improve cerebral blood circulation and neuroprotection: protect the ischemic penumbra that has not yet been necrotic, emphasize neuroprotection while thrombolysis, and reduce neurocytopathy caused by ischemia Extent and scope, prolong neuron survival, clinically achieve the purpose of reducing mortality and disability rate, and improving the quality of life


    Measures to improve cerebral blood circulation include intravenous thrombolysis, antiplatelet, anticoagulation, defibrillation and other drugs and intravascular treatments (such as intravascular mechanical thrombectomy) to achieve rapid blood flow recovery


    In the early stage of SHPL-49, Shanghai University of Traditional Chinese Medicine completed drug discovery and drug-ready research


    In March 2019, the patent application materials were transferred to Shanghai Hutchison Pharmaceuticals.


    Source: Shanghai Hutchison Pharmaceutical Co.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.